Table 1 Serum concentration of osteopontin (OPN) and thrombospondin-1 (TSP-1) according to baseline patients characteristics
No (%) | OPN serum level | TSP-1 serum level | |||
|---|---|---|---|---|---|
Median (range) | p value | Median (range) | p value | ||
Population | |||||
Controls | 20 | 8.8 (4–46) | 31 (0–12060) | ||
Patients | 171 (100) | 27.6 (7–191) | <1.10e-5 | 14520 (2946–30940) | <1.10e-5 |
Age, years (range) | |||||
<65 | 138 (81) | 26.3 (7–89) | 15057 (3979–30938) | ||
≥65 | 33 (19) | 32.1 (9–191) | 0.07 | 13171 (2946–22011) | 0.01 |
Sex | |||||
Female | 62 (36) | 26.6 (7–89) | 14910 (2946–30938) | ||
Male | 109 (64) | 28.2 (8–191) | 0.17 | 13980 (3381–26077) | 0.31 |
Smoking history | |||||
Current | 87 (51) | 27.9 (7–88) | 15062 (2946–30938) | ||
Former | 56 (33) | 27.9 (7–191) | 13171 (3381–26077) | ||
Never | 27 (16) | 25.0 (9–89) | 0.85 | 14762 (5564–20468) | 0.17 |
p TNM | |||||
IA | 40 (23) | 23.3 (11–89) | 15270 (3381–25112) | ||
IB | 41 (24) | 24.5 (7–87) | 13120 (4899–26906) | ||
IIA | 21 (12) | 26.7 (8–88) | 12928 (7047–24731) | ||
IIB | 16 (9) | 30.1 (9–78) | 14440 (9043–23813) | ||
IIIA | 40 (24) | 33.4 (8–148) | 13639 (5450–30938) | ||
IIIB | 5 (3) | 37.5 (17–191) | 14816 (12862–20606) | ||
IV | 8 (5) | 26.4 (9–64) | 0.17 | 16332 (2946–22299) | 0.75 |
Stage | |||||
I-II-IIIA | 158 (92) | 27.4 (7–148) | 14423 (3381–30938) | ||
IIIB | 13 (8) | 29.6 (9–191) | 0.75 | 16324 (2946–22299) | 0.23 |
Tumor size | |||||
<5 cm | 125 (74) | 23.3 (7–89) | 14107 (2946–30938) | ||
≥5cm | 43 (26) | 34.6 (9–191) | <1.10e-5 | 15057 (5450.5-23813) | 0.53 |
Type of resection | |||||
Wedge | 22 (14) | 26.11 (8–89) | 13403 (2946–22299) | ||
Lobectomy | 123 (77) | 26.8 (7–148) | 15062.(3381–26906) | ||
Bi-lobectomy | 6 (4) | 31.2 (12–191) | 15804(11052–21302) | ||
Pneumonectomy | 9 (6) | 38.3 (9–85) | 0.17 | 10526 (5929–30938) | 0.07 |
Resection margins | |||||
Clear | 165 (98) | 27.2 (7–191) | 14519 (2946–30938) | ||
Involved | 4 (2) | 54.5 (9–75) | 0.26 | 15410 (12605–22011) | 0.43 |
Histologic subtype | |||||
Adenocarcinoma | 108 (63) | 25.3 (7–148) | 14799 (2946–26906) | ||
Squamous cell carcinoma | 40 (23) | 32.8 (8–88) | 13032 (5327–30938) | ||
Large cell carcinoma | 8 (5) | 36.3 (21–72) | 15720 (12480–22299) | ||
Other | 15 (9) | 29.6 (9–191) | 0.06 | 12605 (5564–24731) | 0.29 |
Lympho-vasc. invasion | |||||
Yes | 42 (26) | 28.4 (9–191) | 14202 (2946–24731) | ||
No | 123 (75) | 27.6 (7–148) | 0.47 | 14567 (3979–30938) | 0.75 |
Pleural invasion | |||||
Yes | 74 (46) | 28.3 (7–191) | 13811 (2946–26077) | ||
No | 86 (54) | 26.9 (8–89) | 0.36 | 15247 (3381–30938) | 0.27 |
Adjuvant treatment | |||||
Yes | 48 (29) | 28.1 (7–191) | 14608 (5327–24731) | ||
No | 120 (71) | 26.9 (8–148) | 0.69 | 14543 (2946–30938] | 0.66 |
EGFR status | |||||
Wild-type | 112 (90) | 26.8 (7–191) | 13752 (2946–26906) | ||
Mutation | 12 (10) | 24.6 (10–38) | 0.37 | 15984 (10111–22165) | 0.23 |
KRAS status | |||||
Wild-type | 78 (62) | 27.4 (7–188) | 13171 (2946–26906) | ||
Mutation | 48 (38) | 24.7 (7–191) | 0.37 | 15323 (5327–25112) | 0.08 |
ALK rearrangement | |||||
Yes | 3 (2) | 29.6 (22–64) | 19801 (14519–22299) | ||
No | 164 (98) | 27.2 (7–191) | 0.50 | 14440 (2946–30938) | 0.13 |